Lucid Diagnostics Announces Pricing of Initial Public Offering
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) — Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced the pricing of its…
